CRP and rheumatoid arthritis: The results of our present retrospective analyses of 106 patients with RA revealed that both the IGU and MTX+IGU treatment groups showed a significant decrease in DAS28-CRP at 54 weeks compared to the baseline, with no significant difference between the two groups.